Generic drug developers don’t lose to “bad luck.” They lose to predictable thinking.
If you’re building a generic pipeline, formulation patents are often treated like a wall you can’t move—something to “wait out” or “work around later.” But the real …

Pharma forensics is the new competitive intelligence.
Most people think formulation patents are “just chemistry.” In reality, they’re often the most strategic documents in a company’s lifecycle playbook—quietly encoding timelines, manufacturing const…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Patent Game
In generic drug development, the first patent is rarely the whole story.
Most teams plan their strategy around the “primary” patent landscape—mechanism-of-action, compo…

Patent cliffs aren’t just a legal event—they’re a supply-chain stress test.
If you work in pharma operations, procurement, or commercial planning, you’ve probably felt the same pattern: a blockbuster’s exclusivity window closes, competitors surge, pric…

Most “prior art” searches fail for the same reason: they’re built on keywords.
In patent work—especially in chemical and biologics—teams often treat search like a scavenger hunt: throw in a few terms, scan results, and hope the right documents surfac…

Pharma’s next IP chess move isn’t “invent around” — it’s “design around.”
If you’re building a product pipeline in a world of crowded patents, you already know the headline: formulation patents can be as blocking as composition-of-matter. But the rea…

Most people read drug patents like they’re reading a recipe. But the real story is in the ingredients list—and the process breadcrumbs.
In formulation-forensics, the “inactive” details aren’t inactive at all. They’re often the most revealing parts of a…

The biosimilar “patent dance” isn’t a formality—it’s the first move in a multi-year chess match.
If you’re a biologics innovator or a biosimilar applicant, the rules of engagement are familiar: exchange lists, negotiate scope, litigate, and—if you’re…

Generic winners don’t “wait” for exclusivity—they engineer it.
In the Paragraph IV world, 180-day exclusivity is often described like a prize at the end of a race. But the real story is that exclusivity is a strategy outcome—built through timing, lit…

The Patent Dance Is No Longer a Choreography—It’s a Strategy Test
If you’re a biologics or biosimilar applicant, you already know the “patent dance” isn’t a metaphor. It’s a sequence of statutory steps that can decide whether you get to market on time—…